Company Overview and News

 
ENLC / Enlink Midstream, LLC null

2018-09-05 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A
ENLC

1
Devon Energy - Next Target: $50

2018-08-31 seekingalpha
Devon Energy did have some minor troubles in its second quarter due to outperforming production costs and hedging losses.
DVN ENLC

10
Why Devon Energy Could Outperform

2018-08-20 seekingalpha - 2
However, it was good to see that unlike a majority of its peers, the company did not increase its CapEx guidance.
APA ENLK CTLR DVN HK HKRCP CLR ENLC

16
No Encore, Deck Still Stacked For Midstream

2018-08-19 seekingalpha
The string of successive positive weeks for midstream ended this week. Midstream stocks were down roughly 1% across MLP and midstream indexes. Canadian Midstream stocks outperformed for the first time in a while. Utilities had a very strong week and the S&P was slightly positive. Oil prices continue to languish, now down 7 straight weeks, while natural gas prices continue to hold firm.
TGE CQP AMID PAGP ENB CEQP HCLP KMI HESM DKL TRP EBBNF OKE PAA ED KMR CVB NEE ENBBF TRP KEYUF LNG GLPRU ENLC ENB GBNXF ETP GLP SEMG TRGP KMRFZ

6
Devon to Sell Non-Core Assets of Delaware Basin to Carrizo

2018-08-16 zacks
Devon Energy Corporation (DVN - Free Report) announced that it has entered into a definitive agreement to monetize its 9,600 net acres of non-core Delaware Basin acreage in Ward and Reeves County. The company sells the non-core asset to Carrizo Oil and Gas, Inc. (CRZO - Free Report) for $215 million. The deal was announced on Aug 14, 2018. The company monetized nearly $4.4 billion worth of assets year to date.
HD ENLK DVN OXY ENLC

 
 
EnLink Midstream, LLC 2018 Q2 - Results - Earnings Call Slides

2018-08-01 seekingalpha
The following slide deck was published by EnLink Midstream, LLC in conjunction with their 2018 Q2 earnings call.
ENLC

1
Devon Energy (DVN) Q2 2018 Results - Earnings Call Transcript

2018-08-01 seekingalpha
Welcome to Devon Energy's second quarter earnings conference call. At this time, all participants are in a listen-only mode. This call is being recorded.
DVN ENLC

 
EnLink Midstream Partners, LP (ENLK) CEO Mike Garberding on Q2 2018 Results - Earnings Call Transcript

2018-08-01 seekingalpha
EnLink Midstream Partners, LP (NYSE:ENLK) Q2 2018 Earnings Conference Call August 1, 2018 9:00 AM ET
ENLK MRO ENLC

 
ENLC / Enlink Midstream, LLC 10-Q (Quarterly Report)

2018-08-01 sec.gov
Document Table of Contents UNITED STATES
ENLC

 
9
MLP Monthly Report: July 2018

2018-07-29 seekingalpha
The July MLP Monthly Report can be found here offering insights on MLP industry news, the asset class’s performance, yields, valuations, and fundamental drivers.
TGE SNSR MLPA AND LIT BFIT GXG SIL KRMA GXF DVN CHII TEP EV ACTX TEGP CHIE GOEX FINX CHIX SRET BOTZ CATH GURX ENLK BWP GURI ALUM MILN ENLC CJHIQ URA BHI LNGR COPX QQQC GURU

 

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 29336T100